Drug Repurposing of Etanercept
Sector
MedTech
Company
Emerging MedTech
Therapeutic Area
Immunology
Treatment Modality
Drug-Device
Product Stage
Clinical
Expertise
Partnering
A medtech-biologics hybrid company advanced a Phase 2 program evaluating etanercept—a well-established TNF inhibitor—repurposed for a new autoimmune indication. The scientific rationale was compelling: established mechanism, known safety, and a clear unmet need within a defined immunologic pathway. The challenge was to reintroduce a familiar biologic through the lens of new disease biology, elevating the Phase 2 data in a way that resonated with scientific audiences and potential pharmaceutical partners. The goal: to catalyze a business development agreement based on credible clinical validation.
Situation
A medtech-biologics hybrid company advanced a Phase 2 program evaluating etanercept—a well-established TNF inhibitor—repurposed for a new autoimmune indication. The scientific rationale was compelling: established mechanism, known safety, and a clear unmet need within a defined immunologic pathway. The challenge was to reintroduce a familiar biologic through the lens of new disease biology, elevating the Phase 2 data in a way that resonated with scientific audiences and potential pharmaceutical partners. The goal: to catalyze a business development agreement based on credible clinical validation.
Situation
Approach
We built a medical communications strategy anchored in creating a cohesive scientific narrative around the Phase 2 results. Our team synthesized mechanistic, biomarker, and clinical data into a clear, evidence-based story that articulated why TNF inhibition was relevant in this new setting and how the Phase 2 signal aligned with underlying immunopathology. We developed a suite of clinical slide decks—including a core scientific narrative deck, an expanded Phase 2 data readout deck, and a BD-ready clinical rationale deck—each tailored for KOLs, cross-functional teams, and prospective partners. These materials provided a structured, visually clear pathway from mechanism to clinical outcomes, with detailed data visualizations, responder analyses, and Phase 3 design justification.
We built a medical communications strategy anchored in creating a cohesive scientific narrative around the Phase 2 results. Our team synthesized mechanistic, biomarker, and clinical data into a clear, evidence-based story that articulated why TNF inhibition was relevant in this new setting and how the Phase 2 signal aligned with underlying immunopathology. We developed a suite of clinical slide decks—including a core scientific narrative deck, an expanded Phase 2 data readout deck, and a BD-ready clinical rationale deck—each tailored for KOLs, cross-functional teams, and prospective partners. These materials provided a structured, visually clear pathway from mechanism to clinical outcomes, with detailed data visualizations, responder analyses, and Phase 3 design justification.
Approach
Results
This integrated med comms approach created a strong throughline between mechanistic plausibility, Phase 2 validation, and partnership value. The result was heightened interest from multiple pharma partners, leading to an exploratory collaboration with a global immunology company. By grounding the story in rigorous clinical science and delivering high-fidelity scientific slide decks, the company transformed its Phase 2 data into a partnership catalyst, validating the asset’s potential in a new therapeutic domain.
This integrated med comms approach created a strong throughline between mechanistic plausibility, Phase 2 validation, and partnership value. The result was heightened interest from multiple pharma partners, leading to an exploratory collaboration with a global immunology company. By grounding the story in rigorous clinical science and delivering high-fidelity scientific slide decks, the company transformed its Phase 2 data into a partnership catalyst, validating the asset’s potential in a new therapeutic domain.
Situation
A medtech-biologics hybrid company advanced a Phase 2 program evaluating etanercept—a well-established TNF inhibitor—repurposed for a new autoimmune indication. The scientific rationale was compelling: established mechanism, known safety, and a clear unmet need within a defined immunologic pathway. The challenge was to reintroduce a familiar biologic through the lens of new disease biology, elevating the Phase 2 data in a way that resonated with scientific audiences and potential pharmaceutical partners. The goal: to catalyze a business development agreement based on credible clinical validation.
Approach
We built a medical communications strategy anchored in creating a cohesive scientific narrative around the Phase 2 results. Our team synthesized mechanistic, biomarker, and clinical data into a clear, evidence-based story that articulated why TNF inhibition was relevant in this new setting and how the Phase 2 signal aligned with underlying immunopathology. We developed a suite of clinical slide decks—including a core scientific narrative deck, an expanded Phase 2 data readout deck, and a BD-ready clinical rationale deck—each tailored for KOLs, cross-functional teams, and prospective partners. These materials provided a structured, visually clear pathway from mechanism to clinical outcomes, with detailed data visualizations, responder analyses, and Phase 3 design justification.
Results
This integrated med comms approach created a strong throughline between mechanistic plausibility, Phase 2 validation, and partnership value. The result was heightened interest from multiple pharma partners, leading to an exploratory collaboration with a global immunology company. By grounding the story in rigorous clinical science and delivering high-fidelity scientific slide decks, the company transformed its Phase 2 data into a partnership catalyst, validating the asset’s potential in a new therapeutic domain.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.